{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:30:26Z","timestamp":1759797026952,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijrobp.2023.02.049","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T02:00:59Z","timestamp":1678154459000},"page":"1069-1078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-5327","authenticated-orcid":false,"given":"Matthew","family":"Richardson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Keall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kneebone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.02.049_bib0001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0002","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"102","author":"Lukka","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0005","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0006","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1259\/bjr.20170807","article-title":"Moderately hypofractionated prostate external-beam radiotherapy: An emerging standard","volume":"91","author":"Martin","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0007","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.2018.79.3257","article-title":"Prostate cancer radiotherapy: An evolving paradigm","volume":"36","author":"Catton","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0008","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2022.06.014","article-title":"Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFIT","volume":"173","author":"Zhou","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0009","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2015.00151","article-title":"Dysuria following stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Janowski","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0011","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(22)00544-7","article-title":"Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy","volume":"23","author":"Martin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: A combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-9-52","article-title":"Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer","volume":"9","author":"Bhattasali","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0014","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fonc.2014.00122","article-title":"Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer","volume":"4","author":"Woo","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fonc.2019.00217","article-title":"Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS)","volume":"9","author":"Pryor","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030731","article-title":"TROG 18.01 phase III randomised clinical trial of the novel integration of new prostate radiation schedules with adjuvant androgen deprivation: NINJA study protocol","volume":"9","author":"Martin","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0017","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.03.014","article-title":"Real-time image guided ablative prostate cancer radiation therapy: Results from the TROG 15.01 SPARK trial","volume":"107","author":"Keall","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0018","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0019","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jmrs.485","article-title":"Visualising the urethra for prostate radiotherapy planning","volume":"68","author":"Richardson","year":"2021","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0020","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1088\/1361-6560\/62\/8\/3003","article-title":"MRI micturating urethrography for improved urethral delineation in prostate radiotherapy planning: A case study","volume":"62","author":"Rai","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.652678","article-title":"Influence of urethra sparing on tumor control probability and normal tissue complication probability in focal dose escalated hypofractionated radiotherapy: A planning study based on histopathology reference","volume":"11","author":"Spohn","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0022","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0023","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0026","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12885-017-3164-1","article-title":"Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: The TROG 15.01 SPARK trial","volume":"17","author":"Keall","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0027","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12885-018-4511-6","article-title":"PROstate multicentre external beam radiotherapy using a stereotactic boost: The PROMETHEUS study protocol","volume":"18","author":"Richardson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4236\/ijmpcero.2021.103012","article-title":"Constraint analysis and bladder wall low-dose-constraint reduction in five-fraction urethra-sparing prostate SBRT","volume":"10","author":"Prado","year":"2021","journal-title":"Int J Med Phys Clin Eng Radiat Oncol"},{"issue":"suppl 3","key":"10.1016\/j.ijrobp.2023.02.049_bib0029","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1152\/physrev.00030.2012","article-title":"Urothelial signaling","volume":"93","author":"Birder","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0031","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-020-01344-w","article-title":"How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods","volume":"18","author":"Mouelhi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0032","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0033","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0034","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0035","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/cam4.2966","article-title":"Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phro.2021.03.002","article-title":"Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer","volume":"18","author":"Yoshimura","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0037","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.adro.2019.03.015","article-title":"Results of a prospective dose escalation study of linear accelerator\u2013based virtual brachytherapy (BOOSTER) for prostate cancer; Virtual HDR brachytherapy for prostate cancer","volume":"4","author":"Eade","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.049_bib0038","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2019.11.017","article-title":"Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy","volume":"144","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:07:15Z","timestamp":1759745235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0360301623002067"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.049","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}